The Rising Influence of Rising Affluence

[DewDiligence]

ABT 4Q23 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  43%       +17% 
 Nutrition         20%       +13% 
 Diagnostics       25%       -22%† 
 Pharmaceuticals‡  12%        +9%

61% of overall corporate sales were ex-US.

*Includes diabetes care.
‡Branded generics and biosimilars in emerging markets.

†4Q23 COVID-diagnostics sales were $288M (11% of total 4Q23 diagnostic sales) vs $1.07B in 3Q22; excluding COVID diagnostics, 4Q23 diagnostics sales were +2% YoY.